PharmaEssentia Corporation announced five upcoming presentations for the ASCO Annual Meeting and the EHA 2026 Congress. These presentations will feature new clinical data supporting Ropeginterferon Alfa-2b use in essential thrombocythemia.
The ASCO meeting takes place May 29-June 2 in Chicago. Meanwhile, the EHA2026 Congress occurs June 11-14 in Stockholm.
The company will share new analyses from the Phase 3 SURPASS-ET study. This trial evaluates Ropeginterferon Alfa-2b in patients with essential thrombocythemia.
Data show improved progression-free survival at 24 months with early treatment initiation. Patients starting early achieved a 76.9% survival rate. Delayed initiation resulted in a 43.1% survival rate.
Clinical Trial Findings
Integrated analysis of the SURPASS-ET and Phase 2b EXCEED-ET trials includes 182 patients. Results show consistent clinical benefit across treatment lines. Efficacy remained steady across driver mutation subtypes and various patient ethnicities.
M.D., co-principal investigator, presenting author, and President of Advocate Health Cancer National Service Line, Ruben Mesa, highlighted the impact of these clinical developments.
“These findings represent an important step forward in understanding the potential use of interferon-based approaches in essential thrombocythemia.”
He also emphasized the expanding evidence for this investigational treatment.
“Together, these data continue to build on the growing body of evidence supporting the use of ropeginterferon alfa-2b in ET and reinforce its potential role as a meaningful treatment option for patients.”
The drug is currently FDA-approved as BESREMi for adults with polycythemia vera. The FDA is reviewing it for essential thrombocythemia. The PDUFA goal date is August 30, 2026.
Additional data includes real-world findings from 11,809 U.S. veterans with polycythemia vera. An online abstract will also evaluate accelerated dosing titration strategies.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
